본문 바로가기
KERD
논문KCI 등재

Emotional and cognitive changes in chronic kidney disease

길효욱|김덕수|Seong-Wook Kim
대한내과학회 (The Korean Association Of Internal Medicine)|2022.05|The Korean Journal of Internal Medicine|제37권 제3호|pp. 489-501|DOI https://doi.org/10.3904/kjim.2021.492

6

조회

0

다운로드

2

인용

0

참고문헌

키워드

Cognitive dysfunctionBrainDepressive disorderchronicKidney failureUremia
주제분류내과학

초록

Chronic kidney disease (CKD) leads to cognitive impairment and emotional changes. However, the precise mechanism underlying the crosstalk between the kidneys and the nervous system is not fully understood. Inflammation and cerebrovascular disease can influence the development of depression in CKD. CKD is one of the strongest risk factors for cognitive impairment. Moreover, cognitive impairment occurs in CKD as patients experience the dysregulation of several brain functional domains due to damage caused to multiple cortical regions and to subcortical modulatory neurons. The differences in structural brain changes between CKD and non-CKD dementia may be attributable to the different mechanisms that occur in CKD. The kidney and brain have similar anatomical vascular systems, which may be susceptible to traditional risk factors. Vascular factors are assumed to be involved in the development of cognitive impairment in patients with CKD. Vascular injury induces white matter lesions, silent infarction, and microbleeds. Uremic toxins may also be directly related to cognitive impairment in CKD. Many uremic toxins, such as indoxyl sulfate, are likely to have an impact on the central nervous system. Further studies are required to identify therapeutic targets to prevent changes in the brain in patients with CKD.

Abstract

Chronic kidney disease (CKD) leads to cognitive impairment and emotional changes. However, the precise mechanism underlying the crosstalk between the kidneys and the nervous system is not fully understood. Inflammation and cerebrovascular disease can influence the development of depression in CKD. CKD is one of the strongest risk factors for cognitive impairment. Moreover, cognitive impairment occurs in CKD as patients experience the dysregulation of several brain functional domains due to damage caused to multiple cortical regions and to subcortical modulatory neurons. The differences in structural brain changes between CKD and non-CKD dementia may be attributable to the different mechanisms that occur in CKD. The kidney and brain have similar anatomical vascular systems, which may be susceptible to traditional risk factors. Vascular factors are assumed to be involved in the development of cognitive impairment in patients with CKD. Vascular injury induces white matter lesions, silent infarction, and microbleeds. Uremic toxins may also be directly related to cognitive impairment in CKD. Many uremic toxins, such as indoxyl sulfate, are likely to have an impact on the central nervous system. Further studies are required to identify therapeutic targets to prevent changes in the brain in patients with CKD.

참고문헌 (99)

  1. 박지인, "Prevalence of Chronic Kidney Disease in Korea: the Korean National Health and Nutritional Examination Survey 2011-2013", Journal of Korean Medical Science, 31(6), pp.915~923 (2016), 대한의학회
  2. Yongcheol Kim, "Clinical characteristics of spontaneous coronary artery dissection in young female patients with acute myocardial infarction in Korea", The Korean Journal of Internal Medicine, 36(1), pp.106~113 (2021), 대한내과학회[DOI]
  3. Kang Yeunmi, "Clinical outcomes among hemodialysis patients with atrial fibrillation: a Korean nationwide population-based study", Kidney Research and Clinical Practice, 40(1), pp.99~108 (2021), 대한신장학회[DOI]
  4. Su Woong Jung, "The role of inflammation in diabetic kidney disease", The Korean Journal of Internal Medicine, 36(4), pp.753~766 (2021), 대한내과학회[DOI]
  5. Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
  6. Basile David P., "T helper 17 cells in the pathophysiology of acute and chronic kidney disease", Kidney Research and Clinical Practice, 40(1), pp.12~28 (2021), 대한신장학회[DOI]
  7. So Mi Kim, "The clinical impact of gut microbiota in chronic kidney disease", The Korean Journal of Internal Medicine, 35(6), pp.1305~1316 (2020), 대한내과학회[DOI]
  8. Meryl Nath, "New insights into the role of heme oxygenase-1 in acute kidney injury", Kidney Research and Clinical Practice, 39(4), pp.387~401 (2020), 대한신장학회[DOI]
  9. Chillon JM, "Neurological disorders in a murine model of chronic renal failure", Toxins(Basel), 6, pp.180~193 (2014)
  10. Bugnicourt JM, "Cognitive disorders and dementia in CKD : the neglected kidney-brain axis", J Am Soc Nephrol, 24, pp.353~363 (2013)
  11. Tsuruya K, "Brain atrophy and cognitive impairment in chronic kidney disease", Contrib Nephrol, 196, pp.27~36 (2018)
  12. Zalai D, "Psychological distress and depression in patients with chronic kidney disease", Semin Dial, 25, pp.428~438 (2012)
  13. Jabbari B, "The nature, consequences, and management of neurological disorders in chronic kidney disease", Hemodial Int, 22, pp.150~160 (2018)
  14. Tanaka S, "Crosstalk between the nervous system and the kidney", Kidney Int, 97, pp.466~476 (2020)
  15. Hobson P, "How common are neurocognitive disorders in patients with chronic kidney disease and diabetes? : results from a cross-sectional study in a community cohort of patients in North Wales, UK", BMJ Open, 8, pp.e023520~ (2018)
  16. Brodski J, "A systematic review of cognitive impairments associated with kidney failure in adults before natural age-related changes", J Int Neuropsychol Soc, 25, pp.101~114 (2019)
  17. Murtagh FE, "The prevalence of symptoms in end-stage renal disease : a systematic review", Adv Chronic Kidney Dis, 14, pp.82~99 (2007)
  18. Gonzalez AM, "Patient and caregiver priorities for outcomes in CKD : a multinational nominal group technique study", Am J Kidney Dis, 76, pp.679~689 (2020)
  19. Huang CW, "Prevalence and risk factors for elevated anxiety symptoms and anxiety disorders in chronic kidney disease : a systematic review and meta-analysis", Gen Hosp Psychiatry, 69, pp.27~40 (2021)
  20. Loosman WL, "Association of depressive and anxiety symptoms with adverse events in Dutch chronic kidney disease patients : a prospective cohort study", BMC Nephrol, 16, pp.155~ (2015)
  21. Ng HJ, "Prevalence and patterns of depression and anxiety in hemodialysis patients : a 12-month prospective study on incident and prevalent populations", Br J Health Psychol, 20, pp.374~395 (2015)
  22. Waraich P, "Prevalence and incidence studies of mood disorders : a systematic review of the literature", Can J Psychiatry, 49, pp.124~138 (2004)
  23. Palmer S, "Prevalence of depression in chronic kidney disease : systematic review and meta-analysis of observational studies", Kidney Int, 84, pp.179~191 (2013)
  24. Berger I, "Cognition in chronic kidney disease : a systematic review and meta-analysis", BMC Med, 14, pp.206~ (2016)
  25. Watnick S, "Validation of 2depression screening tools in dialysis patients", Am J Kidney Dis, 46, pp.919~924 (2005)
  26. Hedayati SS, "The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients", Kidney Int, 69, pp.1662~1668 (2006)
  27. Hedayati SS, "Validation of depression screening scales in patients with CKD", Am J Kidney Dis, 54, pp.433~439 (2009)
  28. Oberg BP, "Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease", Kidney Int, 65, pp.1009~1016 (2004)
  29. 김애진, "Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients", Kidney Research and Clinical Practice, 40(1), pp.109~119 (2021), 대한신장학회[DOI]
  30. Katon WJ, "Epidemiology and treatment of depression in patients with chronic medical illness", Dialogues Clin Neurosci, 13, pp.7~23 (2011)
  31. Kim SW, "Knockdown of phospholipase C-β1 in the medial prefrontal cortex of male mice impairs working memory among multiple schizophrenia endophenotypes", J Psychiatry Neurosci, 40, pp.78~88 (2015)
  32. Koh HY, "Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1", Genes Brain Behav, 7, pp.120~128 (2008)
  33. Zhang N, "S-SCAM, a rare copy number variation gene, induces schizophrenia-related endophenotypes in transgenic mouse model", J Neurosci, 35, pp.1892~1904 (2015)
  34. McOmish CE, "PLC-beta1knockout mice as a model of disrupted cortical development and plasticity : behavioral endophenotypes and dysregulation of RGS4 gene expression", Hippocampus, 18, pp.824~834 (2008)
  35. Yang Y, "Ketamine blocks bursting in the lateral habenula to rapidly relieve depression", Nature, 554, pp.317~322 (2018)
  36. Park JH, "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease", Sci Adv, 5, pp.eaav0316~ (2019)
  37. MacDonald DI, "A central mechanism of analgesia in mice and humans lacking the sodium channel NaV1. 7", Neuron, 109, pp.1497~1512 (2021)
  38. McCormack K, "Some new insights into the effects of opioids in phasic and tonic nociceptive tests", Pain, 78, pp.79~98 (1998)
  39. D’Hooge R, "Applications of the Morris water maze in the study of learning and memory", Brain Res Brain Res Rev, 36, pp.60~90 (2001)
  40. Webster SJ, "Using mice to model Alzheimer’s dementia : an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models", Front Genet, 5, pp.88~ (2014)
  41. Gawel K, "Assessment of spatial learning and memory in the Barnes maze task in rodents-methodological consideration", Naunyn Schmiedebergs Arch Pharmacol, 392, pp.1~18 (2019)
  42. Olton DS, "The radial arm maze as a tool in behavioral pharmacology", Physiol Behav, 40, pp.793~797 (1987)
  43. Wahl D, "Cognitive and behavioral evaluation of nutritional interventions in rodent models of brain aging and dementia", Clin Interv Aging, 12, pp.1419~1428 (2017)
  44. McOmish CE, "Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration", Mol Psychiatry, 13, pp.661~672 (2008)
  45. Kim HY, "EPPS rescues hippocampus-dependent cognitive deficits in APP", PS1 mice by disaggregation of amyloid-β oligomers and plaques, 2015, pp.6, 8997~
  46. Jo S, "GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease", Nat Med, 20, pp.886~896 (2014)
  47. Likhtik E, "Prefrontal entrainment of amygdala activity signals safety in learned fear and innate anxiety", Nat Neurosci, 17, pp.106~113 (2014)
  48. Won H, "Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function", Nature, 486, pp.261~265 (2012)
  49. Wang X, "Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3", Hum Mol Genet, 20, pp.3093~3108 (2011)
  50. Yang Y, "Novel oxytocin receptor agonists and antagonists : a patent review(2002-2013)", Expert Opin Ther Pat, 24, pp.29~46 (2014)
  51. Li M, "Antipsychotic drugs on maternal behavior in rats", Behav Pharmacol, 26, pp.616~626 (2015)
  52. Cui Y, "Astroglial Kir4. 1 in the lateral habenula drives neuronal bursts in depression", Nature, 554, pp.323~327 (2018)
  53. Shin J, "et al Phospholipase C beta 4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors", J Neurosci, 29, pp.15375~15385 (2009)
  54. Padilla-Coreano N, "Direct ventral hippocampal-prefrontal input is required for anxiety-related neural activity and behavior", Neuron, 89, pp.857~866 (2016)
  55. Adhikari A, "Synchronized activity between the ventral hippocampus and the medial prefrontal cortex during anxiety", Neuron, 65, pp.257~269 (2010)
  56. Bali A, "Stress and opioids : role of opioids in modulating stress-related behavior and effect of stress on morphine conditioned place preference", Neurosci Biobehav Rev, 51, pp.138~150 (2015)
  57. Ali BH, "influence of acacia gum treatment", Exp Biol Med(Maywood), 236, pp.107~112 (2011)
  58. Topczewska-Bruns J, "Behavioral changes in the course of chronic renal insufficiency in rats", Pol J Pharmacol, 53, pp.263~269 (2001)
  59. Ballesta JJ, "Selective down-regulation of α4β2 neuronal nicotinic acetylcholine receptors in the brain of uremic rats with cognitive impairment", Exp Neurol, 236, pp.28~33 (2012)
  60. Tothova L, "Chronic renal insufficiency does not induce behavioral and cognitive alteration in rats", Physiol Behav, 138, pp.133~140 (2015)
  61. Mazumder MK, "A highly reproducible mice model of chronic kidney disease : evidences of behavioural abnormalities and blood-brain barrier disruption", Life Sci, 161, pp.27~36 (2016)
  62. Yu YH, "Altered emotional phenotypes in chronic kidney disease following 5", 6nephrectomy, 2021, pp.11, 882~
  63. Bobot M, "Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction", J Am Soc Nephrol, 31, pp.1509~1521 (2020)
  64. Karbowska M, "Neurobehavioral effects of uremic toxin-indoxyl sulfate in the rat model", Sci Rep, 10, pp.9483~ (2020)
  65. Lv Z, "Uremia-caused changes of ghrelin system in hippocampus may be associated with impaired cognitive function of hippocampus", Int Urol Nephrol, 48, pp.807~815 (2016)
  66. Renczes E, "Behavioral changes during development of chronic kidney disease in rats", Front Med(Lausanne), 6, pp.311~ (2020)
  67. Goh ZS, "Anxiety and depression in patients with endstage renal disease : impact and management challenges : a narrative review", Int J Nephrol Renovasc Dis, 11, pp.93~102 (2018)
  68. Otobe Y, "prevalence and association with physical function", Nephrology(Carlton), 24, pp.50~55 (2019)
  69. Nicholas P, "A cross-sectional study exploring cognitive impairment in kidney failure", J Ren Care (2021)[DOI]
  70. Thancharoen O, "Cognitive impairment, quality of life and healthcare utilization in patients with chronic kidney disease stages 3 to 5", Nephrology(Carlton), 25, pp.625~633 (2020)
  71. Viggiano D, "Mechanisms of cognitive dysfunction in CKD", Nat Rev Nephrol, 16, pp.452~469 (2020)
  72. van der Flier WM, "Epidemiology and risk factors of dementia", J Neurol Neurosurg Psychiatry, 76(Suppl 5), pp.v2~v7 (2005)
  73. Kurella Tamura M, "Dementia and cognitive impairment in ESRD : diagnostic and therapeutic strategies", Kidney Int, 79, pp.14~22 (2011)
  74. Kuo YT, "Risk of dementia in patients with end-stage renal disease under maintenance dialysis : a nationwide population-based study with consideration of competing risk of mortality", Alzheimers Res Ther, 11, pp.31~ (2019)
  75. Sheladia S, "Age-related chronic diseases and Alzheimer’s disease in Texas : a Hispanic focused study", J Alzheimers Dis Rep, 5, pp.121~133 (2021)
  76. Lizio R, "Different abnormalities of cortical neural synchronization mechanisms in patients with mild cognitive impairment due to Alzheimer’s and chronic kidney diseases : an EEG study", J Alzheimers Dis, 65, pp.897~915 (2018)
  77. Jones DJ, "The nature of impairments of memory in patients with end-stage renal disease(ESRD)", Physiol Behav, 147, pp.324~333 (2015)
  78. 김종완, "Chronic renal failure induces cell death in rat hippocampal CA1 via upregulation of aCaMKII", NR2A synaptic complex and phosphorylated GluR1-containing AMPA receptor cascades, 2014, pp.33(3), 132~138[DOI]
  79. Lee JH, "TUDCA-treated mesenchymal stem cells protect against ER stress in the hippocampus of a murine chronic kidney disease model", Int J Mol Sci, 20, pp.613~ (2019)
  80. Mazumder MK, "Neurological sequel of chronic kidney disease : from diminished Acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain", Sci Rep, 9, pp.3097~ (2019)
  81. Griva K, "Cognitive functioning pre-to post-kidney transplantation : a prospective study", Nephrol Dial Transplant, 21, pp.3275~3282 (2006)
  82. Song SH, "Cerebral glucose metabolism abnormalities in patients with major depressive symptoms in pre-dialytic chronic kidney disease : statistical parametric mapping analysis of F-18-FDG PET, a preliminary study", Psychiatry Clin Neurosci, 62, pp.554~561 (2008)
  83. Puy L, "Cognitive impairments and dysexecutive behavioral disorders in chronic kidney disease", J Neuropsychiatry Clin Neurosci, 30, pp.310~317 (2018)
  84. Yaffe K, "Chronic kidney disease and cognitive function in older adults : findings from the chronic renal insufficiency cohort cognitive study", J Am Geriatr Soc, 58, pp.338~345 (2010)
  85. Burns CM, "Prevalence and risk of severe cognitive impairment in advanced chronic kidney disease", J Gerontol A Biol Sci Med Sci, 73, pp.393~399 (2018)
  86. Lee S, "The association between kidney function and cognitive decline in community-dwelling, elderly Japanese people", J Am Med Dir Assoc, 16, pp.349~ (2015)
  87. Hildebrandt F, "Genetic kidney diseases", Lancet, 375, pp.1287~1295 (2010)
  88. Koren-Morag N, "Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease", Neurology, 67, pp.224~228 (2006)
  89. Jiang XL, "Cerebral blood flow changes in hemodialysis and peritoneal dialysis patients : an arterial-spin labeling MR imaging", Metab Brain Dis, 31, pp.929~936 (2016)
  90. Cheng BC, "Decreased cerebral blood flow and improved cognitive function in patients with end-stage renal disease after peritoneal dialysis : an arterial spin-labelling study", Eur Radiol, 29, pp.1415~1424 (2019)
  91. Liu HS, "Regional cerebral blood flow in children and young adults with chronic kidney disease", Radiology, 288, pp.849~858 (2018)
  92. Weiner DE, "Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders", Am J Kidney Dis, 53, pp.438~447 (2009)
  93. Debette S, "The clinical importance of white matter hyperintensities on brain magnetic resonance imaging : systematic review and meta-analysis", BMJ, 341, pp.c3666~ (2010)
  94. Khatri M, "Chronic kidney disease is associated with white matter hyperintensity volume : the Northern Manhattan Study(NOMAS)", Stroke, 38, pp.3121~3126 (2007)
  95. Watanabe K, "Cerebro-renal interactions : impact of uremic toxins on cognitive function", Neurotoxicology, 44, pp.184~193 (2014)
  96. Niwa T, "Indoxyl sulfate is a nephro-vascular toxin", J Ren Nutr, 20(5 Suppl), pp.S2~S6 (2010)
  97. Dou L, "The cardiovascular effect of the uremic solute indole-3 acetic acid", J Am Soc Nephrol, 26, pp.876~887 (2015)
  98. Adesso S, "Indoxyl sulfate affects glial function increasing oxidative stress and neuroinflammation in chronic kidney disease : interaction between astrocytes and microglia", Front Pharmacol, 8, pp.370~ (2017)
  99. Lin YT, "Indoxyl sulfate induces apoptosis through oxidative stress and mitogen-activated protein kinase signaling pathway inhibition in human astrocytes", J Clin Med, 8, pp.191~ (2019)

관련 논문AI추천

Cerebral Small Vessel Disease and Chronic Kidney DiseaseKazunori Toyoda대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제1호Alterations in Structural and Functional Connectivities in Patients with End-Stage Renal Disease김시은, 김양욱, 김일환, 박강민, 박봉수, 박시형, 박진한, 서솔아, 이유진, 이호준대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제3호Relationship between Cognitive Impairment and Depression in Dialysis Patients정산, 노정우, 이영기, 최선령, 황성희연세대학교의과대학 · Yonsei Medical Journal2013 · 제54권 제6호The Correlations among Depressive Symptoms, Cognitive Performance and Serum BDNF Levels in the Patients with Chronic Kidney Disease박성우, 서미경, 이정구, Kyubok Jin, Min Kyung Park, Yang Wook Kim, Yeong Hoon Kim, Young Hoon Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2018 · 제15권 제2호Association between Dialysis Adequacy and Cognition in Patients with Peritoneal DialysisJeon Dong-Wook, Jung Do-Un, Kang Sun Woo, Kim Sung-Jin, Kim Taehee, Kim Yeong Hoon, Kim Yunmi, Moon Jung-Joon, Shin Dong Jin대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제11호Relationship between Chronic Kidney Disease and Depression in Elderly Koreans Using the 2013 Korea National Health and Nutrition Examination Survey Data김지운, 김현자, 문성진, 이대근대한가정의학회 · Korean Journal of Family Medicine2017 · 제38권 제3호

이 간행물의 다른 논문 (22건)

Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs송상헌, 김상수, 김효진pp. 502-519Omics-based biomarkers for diagnosis and prediction of kidney allograft rejectionHee-Yeon Jung, Byung Ha Chung, Jang-Hee Cho, Yong-Lim Kim, Jeong-Hoon Lim, 이상호, Sun-Hee Park, Chan-Duck Kim, Ji-Young Choipp. 520-533Role of T cells in ischemic acute kidney injury and repair이경호, Hye Ryoun Jangpp. 534-550Is radiological healing alone enough? ‘Can’t take my eyes off’ the mucosaSu Hyun Park, Sang Hyoung Parkpp. 551-552Changes in practice for mechanically ventilated patients: effect of the pain, agitation, and delirium guidelinesJin Won Huhpp. 553-554
원문 보기